Paul D. Thompson, MD, FACC

Thompson

General Statement of Disclosure:

EQUITY INTERESTS/STOCK OPTIONS: Moderna(SIGNIFICANT), Shockwave Medical(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Esperion Pharmaceuticals(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Sarepta(SIGNIFICANT), CVS(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Abbvie(SIGNIFICANT), Medtronic(NONE), Johnson & Johnson(SIGNIFICANT), Elsevier(SIGNIFICANT), MJH Life Sciences(MODEST)

View Full Disclosure